Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Identifieur interne : 000E74 ( Main/Exploration ); précédent : 000E73; suivant : 000E75Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Auteurs : Loh-Shan B. Leung [États-Unis] ; Joel W. Neal [États-Unis] ; Heather A. Wakelee [États-Unis] ; Lecia V. Sequist [États-Unis] ; Michael F. Marmor [États-Unis]Source :
- American journal of ophthalmology [ 1879-1891 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Angiographie fluorescéinique, Antinéoplasiques (usage thérapeutique), Antirhumatismaux (administration et posologie), Antirhumatismaux (effets indésirables), Association de médicaments, Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Champs visuels, Chlorhydrate d'erlotinib (usage thérapeutique), Femelle, Humains, Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Mâle, Rétine (), Rétine (anatomopathologie), Rétinopathies (), Rétinopathies (diagnostic), Sujet âgé, Tests du champ visuel, Tomographie par cohérence optique, Tumeurs du poumon (traitement médicamenteux), Électrorétinographie, Études rétrospectives.
- MESH :
- administration et posologie : Antirhumatismaux, Hydroxychloroquine.
- anatomopathologie : Rétine.
- diagnostic : Rétinopathies.
- effets indésirables : Antirhumatismaux, Hydroxychloroquine.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Antinéoplasiques, Chlorhydrate d'erlotinib.
- Adulte d'âge moyen, Angiographie fluorescéinique, Association de médicaments, Champs visuels, Femelle, Humains, Mâle, Rétine, Rétinopathies, Sujet âgé, Tests du champ visuel, Tomographie par cohérence optique, Électrorétinographie, Études rétrospectives.
English descriptors
- KwdEn :
- Aged, Antineoplastic Agents (therapeutic use), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Carcinoma, Non-Small-Cell Lung (drug therapy), Drug Therapy, Combination, Electroretinography, Erlotinib Hydrochloride (therapeutic use), Female, Fluorescein Angiography, Humans, Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Lung Neoplasms (drug therapy), Male, Middle Aged, Retina (drug effects), Retina (pathology), Retinal Diseases (chemically induced), Retinal Diseases (diagnosis), Retrospective Studies, Tomography, Optical Coherence, Visual Field Tests, Visual Fields.
- MESH :
- chemical , administration & dosage : Antirheumatic Agents, Hydroxychloroquine.
- chemical , adverse effects : Antirheumatic Agents, Hydroxychloroquine.
- chemical , therapeutic use : Antineoplastic Agents, Erlotinib Hydrochloride.
- chemically induced : Retinal Diseases.
- diagnosis : Retinal Diseases.
- drug effects : Retina.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Retina.
- Aged, Drug Therapy, Combination, Electroretinography, Female, Fluorescein Angiography, Humans, Male, Middle Aged, Retrospective Studies, Tomography, Optical Coherence, Visual Field Tests, Visual Fields.
Abstract
To report rapid onset of retinal toxicity in a series of patients followed on high-dose (1000 mg daily) hydroxychloroquine during an oncologic clinical trial studying hydroxychloroquine with erlotinib for non-small cell lung cancer.
DOI: 10.1016/j.ajo.2015.07.012
PubMed: 26189086
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000242
- to stream PubMed, to step Curation: 000242
- to stream PubMed, to step Checkpoint: 000226
- to stream Ncbi, to step Merge: 000303
- to stream Ncbi, to step Curation: 000303
- to stream Ncbi, to step Checkpoint: 000303
- to stream Main, to step Merge: 000E75
- to stream Main, to step Curation: 000E74
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.</title><author><name sortKey="Leung, Loh Shan B" sort="Leung, Loh Shan B" uniqKey="Leung L" first="Loh-Shan B" last="Leung">Loh-Shan B. Leung</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: lbleung@stanford.edu.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Wakelee, Heather A" sort="Wakelee, Heather A" uniqKey="Wakelee H" first="Heather A" last="Wakelee">Heather A. Wakelee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Marmor, Michael F" sort="Marmor, Michael F" uniqKey="Marmor M" first="Michael F" last="Marmor">Michael F. Marmor</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26189086</idno><idno type="pmid">26189086</idno><idno type="doi">10.1016/j.ajo.2015.07.012</idno><idno type="wicri:Area/PubMed/Corpus">000242</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000242</idno><idno type="wicri:Area/PubMed/Curation">000242</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000242</idno><idno type="wicri:Area/PubMed/Checkpoint">000226</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000226</idno><idno type="wicri:Area/Ncbi/Merge">000303</idno><idno type="wicri:Area/Ncbi/Curation">000303</idno><idno type="wicri:Area/Ncbi/Checkpoint">000303</idno><idno type="wicri:Area/Main/Merge">000E75</idno><idno type="wicri:Area/Main/Curation">000E74</idno><idno type="wicri:Area/Main/Exploration">000E74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.</title><author><name sortKey="Leung, Loh Shan B" sort="Leung, Loh Shan B" uniqKey="Leung L" first="Loh-Shan B" last="Leung">Loh-Shan B. Leung</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: lbleung@stanford.edu.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Wakelee, Heather A" sort="Wakelee, Heather A" uniqKey="Wakelee H" first="Heather A" last="Wakelee">Heather A. Wakelee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Division of Oncology, Stanford University/Stanford Cancer Institute, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Marmor, Michael F" sort="Marmor, Michael F" uniqKey="Marmor M" first="Michael F" last="Marmor">Michael F. Marmor</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author></analytic><series><title level="j">American journal of ophthalmology</title><idno type="eISSN">1879-1891</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Drug Therapy, Combination</term><term>Electroretinography</term><term>Erlotinib Hydrochloride (therapeutic use)</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Lung Neoplasms (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Retina (drug effects)</term><term>Retina (pathology)</term><term>Retinal Diseases (chemically induced)</term><term>Retinal Diseases (diagnosis)</term><term>Retrospective Studies</term><term>Tomography, Optical Coherence</term><term>Visual Field Tests</term><term>Visual Fields</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Angiographie fluorescéinique</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (effets indésirables)</term><term>Association de médicaments</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Champs visuels</term><term>Chlorhydrate d'erlotinib (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Hydroxychloroquine (administration et posologie)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Mâle</term><term>Rétine ()</term><term>Rétine (anatomopathologie)</term><term>Rétinopathies ()</term><term>Rétinopathies (diagnostic)</term><term>Sujet âgé</term><term>Tests du champ visuel</term><term>Tomographie par cohérence optique</term><term>Tumeurs du poumon (traitement médicamenteux)</term><term>Électrorétinographie</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Erlotinib Hydrochloride</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antirhumatismaux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Rétine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Retinal Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Retinal Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Rétinopathies</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Retina</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antirhumatismaux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Retina</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Chlorhydrate d'erlotinib</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Therapy, Combination</term><term>Electroretinography</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Tomography, Optical Coherence</term><term>Visual Field Tests</term><term>Visual Fields</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Angiographie fluorescéinique</term><term>Association de médicaments</term><term>Champs visuels</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Rétine</term><term>Rétinopathies</term><term>Sujet âgé</term><term>Tests du champ visuel</term><term>Tomographie par cohérence optique</term><term>Électrorétinographie</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To report rapid onset of retinal toxicity in a series of patients followed on high-dose (1000 mg daily) hydroxychloroquine during an oncologic clinical trial studying hydroxychloroquine with erlotinib for non-small cell lung cancer.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Leung, Loh Shan B" sort="Leung, Loh Shan B" uniqKey="Leung L" first="Loh-Shan B" last="Leung">Loh-Shan B. Leung</name></region><name sortKey="Marmor, Michael F" sort="Marmor, Michael F" uniqKey="Marmor M" first="Michael F" last="Marmor">Michael F. Marmor</name><name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name><name sortKey="Wakelee, Heather A" sort="Wakelee, Heather A" uniqKey="Wakelee H" first="Heather A" last="Wakelee">Heather A. Wakelee</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26189086
|texte= Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26189086" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |